This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sissom, J. F. Articles by Porter, J. C. Search for Related Content PubMed PubMed Citation Articles by Sissom, J. F. Articles by Porter, J. C.

American Journal of Pathology, Vol 133, 589-595, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor

JF Sissom, ML Eigenbrodt and JC Porter
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235.

Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52%. Female mice were treated with the carcinogen, 7,12- dimethylbenz[a]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13% developed mammary carcinomas, and 16% developed moderate-to- severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8% of the mice had moderate- to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 +/- 1.1 mg (mean +/- SE), and that of mice treated with control antibody was 27 +/- 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.

This article has been cited by other articles:

				D. Zaidi, K. A. James, and G. F. Wagner Passive immunization of lactating mice with stanniocalcin-1 antiserum reduces mammary gland development, milk fat content, and postnatal pup growth Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E974 - E981. [Abstract] [Full Text] [PDF]

				A. Glasow, L.-C. Horn, S. E. Taymans, C. A. Stratakis, P. A. Kelly, U. Kohler, J. Gillespie, B. K. Vonderhaar, and S. R. Bornstein Mutational Analysis of the PRL Receptor Gene in Human Breast Tumors with Differential PRL Receptor Protein Expression J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3826 - 3832. [Abstract] [Full Text] [PDF]

				S. K. Clinton, A. L. Mulloy, S. P. Li, H. J. Mangian, and W. J. Visek Dietary Fat and Protein Intake Differ in Modulation of Prostate Tumor Growth, Prolactin Secretion and Metabolism, and Prostate Gland Prolactin Binding Capacity in Rats J. Nutr., February 1, 1997; 127(2): 225 - 237. [Abstract] [Full Text]